Archive for November 17th, 2009
Montedison, super day suspension with final
Suspension for excessive upward Montedison, which in the final day pit margins bargaining share 2.91 euros. The company is literally for days on a roller coaster, with losses of around 11% in recent sessions, as opposed to an exceptional rebound scored today.
Related posts
General, further fall in the Milan Stock
New fall on the Stock Exchange of Generali, as he approaches the date of the scheduled April 28. Yesterday, the title has yielded 4.08% at 34.2 euros. Goldman Sachs and Warburg revise estimates of the value of the shares, the first that has lowered its price target from 46 to 42 euros, the same value to which Warburg has corrected from 49 euros. Gutty assumptions or longed for the Summit.
Related posts
Pinault Printemps-Redoute, slower growth
The leader in the French group Pinault Printemps-Redoute multidistribuzione reported in the first quarter of 2001, an increase of 23% of its turnover, which reached 6.764 billion euros. Internal growth instead he had sharply since comparable data sales increased by 5.8%, against a growth of 8, 3% in the first quarter of 1999. The stocks traded at 195.9 euros upwards of 1, 03%.
Related posts
General: analysts cut targets
General rebounds after falling yesterday, when he left the field to 4.08%. The title is exchanged at this time at an altitude of 34.80 euros, an increase of 1, 49%. On the General were killed in recent days some reports not much success, the kind issued by Banca IMI, which has cut its price target to 37 euros from 40 due to the poor performance of financial markets that riperquoterà on year-end accounts. The same opinion UBS Warburg, which has cut its target from 49 to 42 euros, because of previous estimates of growth judges following too optimistic. Imi Bank has maintained its hold opinion, as well as UBS, which has reiterated its buy.
Related posts
The six-legged dog runs after the Exxon
CSFB remains positive on LVMH
Biotech, in order to Celltech profits rise
Shares of Celltech, the biotechnology group of British salt by 6.8% after the company has released data for 2000 which were in line with market forecasts. Celltech said that gross profits have grown from 19.6 million pounds to 25.1 million. The group said that the merger with Chiroscience and Medeva has resulted in saving 20 million streline and that will lead to savings of another 25 million in 2001. The more money will be invested by the company in research and development.
Related posts
Swatch 2000 results above expectations
The Swiss Swatch has submitted to the financial community as a result for the year 2000 exceeds the expectations of industry analysts. The profits were 423 million euro, equivalent to a growth of 47.6%. IN Turnover grew by 17.6%. The Board of Governors of the Group decided to propose to shareholders a refund of 55% of the nominal value of shares instead of an ordinary dividend of 5.50 Swiss francs per registered share and CHF 27.50 per bearer share. Swatch also plans a stock split which should divide by ten the present value of the action. Operation which should follow the current trend towards lighter action research by breaking down the barriers of entry as well for small shareholders.